2012). The reason for this is unknown, but patients with T2D generally have an increased risk of developing pancreatitis as well (Noel et al. 2009). As only healthy subjects were included in this study, we cannot exclude that serum lipase levels would change differently following infusions of GLP‐1 and PYY3‐36 in patients with T2D patients, and understanding the mechanism behind the increase in serum lipase that has been reported with Trulicity®, Byetta®, and Victoza® treatment, therefore, requires further studies conducted on this specific population. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.